Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Risk factors for disease progression in idiopathic pulmonary fibrosis.

Raghu G, Ley B, Brown KK, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Noble PW, Song JW, Wells AU, Whelan TP, Lynch DA, Humphries SM, Moreau E, Goodman K, Patterson SD, Smith V, Gong Q, Sundy JS, O'Riordan TG, Martinez FJ.

Thorax. 2019 Oct 14. pii: thoraxjnl-2019-213620. doi: 10.1136/thoraxjnl-2019-213620. [Epub ahead of print]

PMID:
31611341
2.

Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.

Ng B, Dong J, D'Agostino G, Viswanathan S, Widjaja AA, Lim WW, Ko NSJ, Tan J, Chothani SP, Huang B, Xie C, Pua CJ, Chacko AM, Guimarães-Camboa N, Evans SM, Byrne AJ, Maher TM, Liang J, Jiang D, Noble PW, Schafer S, Cook SA.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw1237. doi: 10.1126/scitranslmed.aaw1237.

PMID:
31554736
3.

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW.

Adv Ther. 2019 Oct;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6.

4.

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW.

Adv Ther. 2019 Oct;36(10):2910-2926. doi: 10.1007/s12325-019-01052-y. Epub 2019 Aug 10. Erratum in: Adv Ther. 2019 Sep 9;:.

5.

Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles.

Parimon T, Yao C, Habiel DM, Ge L, Bora SA, Brauer R, Evans CM, Xie T, Alonso-Valenteen F, Medina-Kauwe LK, Jiang D, Noble PW, Hogaboam CM, Deng N, Burgy O, Antes TJ, Königshoff M, Stripp BR, Gharib SA, Chen P.

JCI Insight. 2019 Aug 8;5. pii: 129359. doi: 10.1172/jci.insight.129359.

6.

Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis.

Yang YM, Noureddin M, Liu C, Ohashi K, Kim SY, Ramnath D, Powell EE, Sweet MJ, Roh YS, Hsin IF, Deng N, Liu Z, Liang J, Mena E, Shouhed D, Schwabe RF, Jiang D, Lu SC, Noble PW, Seki E.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaat9284. doi: 10.1126/scitranslmed.aat9284.

PMID:
31189722
7.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

8.

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW.

Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. No abstract available.

9.

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.

Costabel U, Albera C, Glassberg MK, Lancaster LH, Wuyts WA, Petzinger U, Gilberg F, Kirchgaessler KU, Noble PW.

Respir Res. 2019 Mar 12;20(1):55. doi: 10.1186/s12931-019-1021-2.

10.

PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis.

Geng Y, Liu X, Liang J, Habiel DM, Kulur V, Coelho AL, Deng N, Xie T, Wang Y, Liu N, Huang G, Kurkciyan A, Liu Z, Tang J, Hogaboam CM, Jiang D, Noble PW.

JCI Insight. 2019 Mar 21;4(6). pii: 125326. doi: 10.1172/jci.insight.125326. eCollection 2019 Mar 21.

11.

Mitogen-activated Protein Kinase-activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis.

Liang J, Liu N, Liu X, Mena JM, Xie T, Geng Y, Huan C, Zhang Y, Taghavifar F, Huang G, Kurkciyan A, Barron V, Jiang D, Noble PW.

Am J Respir Cell Mol Biol. 2019 Jan;60(1):41-48. doi: 10.1165/rcmb.2018-0033OC.

PMID:
30130411
12.

Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.

Nathan SD, Lancaster LH, Albera C, Glassberg MK, Swigris JJ, Gilberg F, Kirchgaessler KU, Limb SL, Petzinger U, Noble PW.

BMJ Open Respir Res. 2018 Aug 2;5(1):e000323. doi: 10.1136/bmjresp-2018-000323. eCollection 2018.

13.

Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.

Espindola MS, Habiel DM, Narayanan R, Jones I, Coelho AL, Murray LA, Jiang D, Noble PW, Hogaboam CM.

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1443-1456. doi: 10.1164/rccm.201707-1519OC.

14.

Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis.

Xie T, Wang Y, Deng N, Huang G, Taghavifar F, Geng Y, Liu N, Kulur V, Yao C, Chen P, Liu Z, Stripp B, Tang J, Liang J, Noble PW, Jiang D.

Cell Rep. 2018 Mar 27;22(13):3625-3640. doi: 10.1016/j.celrep.2018.03.010.

15.

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA.

Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. Review.

16.

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW.

Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13.

17.

MicroRNA-29c Prevents Pulmonary Fibrosis by Regulating Epithelial Cell Renewal and Apoptosis.

Xie T, Liang J, Geng Y, Liu N, Kurkciyan A, Kulur V, Leng D, Deng N, Liu Z, Song J, Chen P, Noble PW, Jiang D.

Am J Respir Cell Mol Biol. 2017 Dec;57(6):721-732. doi: 10.1165/rcmb.2017-0133OC.

18.

Targeted HAS2 Expression Lessens Airway Responsiveness in Chronic Murine Allergic Airway Disease.

Walker JKL, Theriot BS, Ghio M, Trempus CS, Wong JE, McQuade VL, Liang J, Jiang D, Noble PW, Garantziotis S, Kraft M, Ingram JL.

Am J Respir Cell Mol Biol. 2017 Dec;57(6):702-710. doi: 10.1165/rcmb.2017-0095OC.

19.

miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways.

Ge L, Habiel DM, Hansbro PM, Kim RY, Gharib SA, Edelman JD, Königshoff M, Parimon T, Brauer R, Huang Y, Allen J, Jiang D, Kurkciyan AA, Mizuno T, Stripp BR, Noble PW, Hogaboam CM, Chen P.

JCI Insight. 2016 Dec 8;1(20):e90301. doi: 10.1172/jci.insight.90301.

20.

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.

Raghu G, Brown KK, Collard HR, Cottin V, Gibson KF, Kaner RJ, Lederer DJ, Martinez FJ, Noble PW, Song JW, Wells AU, Whelan TP, Wuyts W, Moreau E, Patterson SD, Smith V, Bayly S, Chien JW, Gong Q, Zhang JJ, O'Riordan TG.

Lancet Respir Med. 2017 Jan;5(1):22-32. doi: 10.1016/S2213-2600(16)30421-0. Epub 2016 Dec 7.

PMID:
27939076
21.

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

Lancet Respir Med. 2017 Jan;5(1):33-41. doi: 10.1016/S2213-2600(16)30326-5. Epub 2016 Nov 19. Erratum in: Lancet Respir Med. 2017 Jan;5(1):e7.

PMID:
27876247
22.

Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice.

Liang J, Zhang Y, Xie T, Liu N, Chen H, Geng Y, Kurkciyan A, Mena JM, Stripp BR, Jiang D, Noble PW.

Nat Med. 2016 Nov;22(11):1285-1293. doi: 10.1038/nm.4192. Epub 2016 Oct 3.

23.

Hyaluronan synthase 2 regulates fibroblast senescence in pulmonary fibrosis.

Li Y, Liang J, Yang T, Monterrosa Mena J, Huan C, Xie T, Kurkciyan A, Liu N, Jiang D, Noble PW.

Matrix Biol. 2016 Sep;55:35-48. doi: 10.1016/j.matbio.2016.03.004. Epub 2016 Mar 15.

24.

Hyaluronan mediates ozone-induced airway hyperresponsiveness in mice.

Garantziotis S, Li Z, Potts EN, Kimata K, Zhuo L, Morgan DL, Savani RC, Noble PW, Foster WM, Schwartz DA, Hollingsworth JW.

J Biol Chem. 2016 Sep 9;291(37):19257-8. doi: 10.1074/jbc.A116.802400. No abstract available.

25.

Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis.

Xie T, Liang J, Liu N, Huan C, Zhang Y, Liu W, Kumar M, Xiao R, D'Armiento J, Metzger D, Chambon P, Papaioannou VE, Stripp BR, Jiang D, Noble PW.

J Clin Invest. 2016 Sep 1;126(9):3626. doi: 10.1172/JCI89968. Epub 2016 Aug 22. No abstract available.

26.

A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors.

Chen Z, Patel JM, Noble PW, Garcia C, Hong Z, Hansen JE, Zhou J.

Oncotarget. 2016 Sep 13;7(37):59965-59975. doi: 10.18632/oncotarget.11015.

27.

Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis.

Xie T, Liang J, Liu N, Huan C, Zhang Y, Liu W, Kumar M, Xiao R, D'Armiento J, Metzger D, Chambon P, Papaioannou VE, Stripp BR, Jiang D, Noble PW.

J Clin Invest. 2016 Aug 1;126(8):3063-79. doi: 10.1172/JCI85328. Epub 2016 Jul 11. Erratum in: J Clin Invest. 2016 Sep 1;126(9):3626.

28.

DNA-damaging autoantibodies and cancer: the lupus butterfly theory.

Noble PW, Bernatsky S, Clarke AE, Isenberg DA, Ramsey-Goldman R, Hansen JE.

Nat Rev Rheumatol. 2016 Jul;12(7):429-34. doi: 10.1038/nrrheum.2016.23. Epub 2016 Mar 24. Review.

PMID:
27009542
29.

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.

Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU.

Thorax. 2016 May;71(5):429-35. doi: 10.1136/thoraxjnl-2015-207011. Epub 2016 Mar 11.

30.

Correction: Ozone Inhalation Promotes CX3CR1-Dependent Maturation of Resident Lung Macrophages That Limit Oxidative Stress and Inflammation.

Tighe RM, Li Z, Potts EN, Frush S, Liu N, Gunn MD, Foster WM, Noble PW, Hollingsworth JW.

J Immunol. 2016 Mar 1;196(5):2424. doi: 10.4049/jimmunol.1600002. No abstract available.

31.

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.

Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW.

BMJ Open Respir Res. 2016 Jan 12;3(1):e000105. doi: 10.1136/bmjresp-2015-000105. eCollection 2016.

32.

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.

Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr.

Eur Respir J. 2016 Jan;47(1):243-53. doi: 10.1183/13993003.00026-2015. Epub 2015 Dec 2.

33.

Pirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis.

Selvaggio AS, Noble PW.

Annu Rev Med. 2016;67:487-95. doi: 10.1146/annurev-med-120214-013614. Epub 2015 Nov 4. Review.

PMID:
26565677
34.

Hyaluronan as a therapeutic target in human diseases.

Liang J, Jiang D, Noble PW.

Adv Drug Deliv Rev. 2016 Feb 1;97:186-203. doi: 10.1016/j.addr.2015.10.017. Epub 2015 Nov 2. Review.

35.

The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome.

DerHovanessian A, Weigt SS, Palchevskiy V, Shino MY, Sayah DM, Gregson AL, Noble PW, Palmer SM, Fishbein MC, Kubak BM, Ardehali A, Ross DJ, Saggar R, Lynch JP 3rd, Elashoff RM, Belperio JA.

Am J Transplant. 2016 Feb;16(2):640-9. doi: 10.1111/ajt.13475. Epub 2015 Oct 13.

36.

Methylation-mediated BMPER expression in fibroblast activation in vitro and lung fibrosis in mice in vivo.

Huan C, Yang T, Liang J, Xie T, Cheng L, Liu N, Kurkciyan A, Monterrosa Mena J, Wang C, Dai H, Noble PW, Jiang D.

Sci Rep. 2015 Oct 7;5:14910. doi: 10.1038/srep14910.

37.

Flow Cytometric Analysis of Myeloid Cells in Human Blood, Bronchoalveolar Lavage, and Lung Tissues.

Yu YR, Hotten DF, Malakhau Y, Volker E, Ghio AJ, Noble PW, Kraft M, Hollingsworth JW, Gunn MD, Tighe RM.

Am J Respir Cell Mol Biol. 2016 Jan;54(1):13-24. doi: 10.1165/rcmb.2015-0146OC.

38.

DNA-dependent targeting of cell nuclei by a lupus autoantibody.

Weisbart RH, Chan G, Jordaan G, Noble PW, Liu Y, Glazer PM, Nishimura RN, Hansen JE.

Sci Rep. 2015 Jul 9;5:12022. doi: 10.1038/srep12022.

39.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Respir Med. 2015 Jul;109(7):914-22. doi: 10.1016/j.rmed.2015.04.008. Epub 2015 Apr 24.

40.

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE Jr, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW.

Chest. 2015 Jul;148(1):196-201. doi: 10.1378/chest.14-2817.

41.

Optimizing a lupus autoantibody for targeted cancer therapy.

Noble PW, Chan G, Young MR, Weisbart RH, Hansen JE.

Cancer Res. 2015 Jun 1;75(11):2285-91. doi: 10.1158/0008-5472.CAN-14-2278. Epub 2015 Apr 1.

42.

Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice.

Dong Y, Geng Y, Li L, Li X, Yan X, Fang Y, Li X, Dong S, Liu X, Li X, Yang X, Zheng X, Xie T, Liang J, Dai H, Liu X, Yin Z, Noble PW, Jiang D, Ning W.

J Exp Med. 2015 Feb 9;212(2):235-52. doi: 10.1084/jem.20121878. Epub 2015 Jan 12.

43.

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, du Bois RM.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205.

PMID:
25363219
44.

Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood.

Meltzer EB, Barry WT, Yang IV, Brown KK, Schwarz MI, Patel H, Ashley A, Noble PW, Schwartz DA, Steele MP.

BMC Genomics. 2014 Oct 16;15:902. doi: 10.1186/1471-2164-15-902.

45.

Treatments for idiopathic pulmonary fibrosis.

King TE Jr, Noble PW, Bradford WZ.

N Engl J Med. 2014 Aug 21;371(8):783-4. doi: 10.1056/NEJMc1407776. No abstract available.

PMID:
25147884
46.

A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells.

Noble PW, Young MR, Bernatsky S, Weisbart RH, Hansen JE.

Sci Rep. 2014 Aug 5;4:5958. doi: 10.1038/srep05958.

47.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM.

Respirology. 2014 Jul;19(5):740-7. doi: 10.1111/resp.12297. Epub 2014 May 18.

48.

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group.

N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. Erratum in: N Engl J Med. 2014 Sep 18;371(12):1172.

49.

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators.

N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum in: N Engl J Med. 2015 Aug 20;373(8):782.

50.

Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis.

Barkauskas CE, Noble PW.

Am J Physiol Cell Physiol. 2014 Jun 1;306(11):C987-96. doi: 10.1152/ajpcell.00321.2013. Epub 2014 Apr 16. Review.

Supplemental Content

Loading ...
Support Center